Lithium stimulated corticotropin (ACTH) secretion by mouse pituitary tumor cells and by normal rat anterior pituitary cells in primary culture. Effects were observed at less than 2 mM LiCl. ACTH secretion was comparable in magnitude to that induced by other secretagogues, was calcium dependent, and was inhibited by somatostatin. Lithium also induced changes in [3H]inositide metabolism; these changes accompanied and were correlated with changes in ACTH secretion. The most prominent and reliable effect was to increase [3H]inositol monophosphate. Other secretagogues had no effect on [3Hlinositides in the presence or absence of lithium. Pretreatment with lithium for 3 hr desensitized the cells to the effects of subsequent exposure to lithium. The cells were not desensitized to lithium by pretreatment with other secretagogues, nor were they desensitized by lithium to the effects of corticotropin-releasing factor, high potassium, or forskolin. However, pretreatment with lithium did desensitize the cells to stimulation by phorbol esters. The interaction between lithium and phorbol esters suggests the involvement of inositide metabolism and protein kinase C in the regulation of ACTH secretion and possibly of other hormones or neurotransmitters. It also suggests new avenues of research into the basis of lithium's psychopharmacological effects.
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In addition to being a monovalent metal, lithium is the major therapeutic agent used in the treatment of manic-depressive disease (1) (2) (3) . Its similarities to several biologically important metals have confounded attempts to understand its mechanism of action as a drug. Lithium has numerous effects on biological systems, but few of them are striking, and most are inhibitory, at the low concentrations that are safe and effective in man (1) (2) (3) .
The discovery (4) that lithium is a potent and specific inhibitor of the phosphatase that cleaves inositol 1-phosphate to inositol connects the action of lithium to the actions of several neurotransmitters and hormones that stimulate inositol phospholipid turnover and calcium mobilization. Receptor-mediated stimulation of phosphatidylinositol turnover (breakdown) and consequent release of diacylglycerol and inositol phosphates has been studied for some time (5) (6) (7) (8) (9) . Current models (10) (11) (12) (13) (14) (15) (16) emphasize the synergistic effects of inositol trisphosphate (InsP3) and diacylglycerol in stimulating the activity of protein kinase C, thus mediating the physiologic effects of these neurotransmitters and hormones. This phospholipid-and calcium-regulated protein kinase (17, 18) responds directly to diacylglycerol and other lipids and indirectly to InsP3 (which mobilizes intracellular calcium, to which the enzyme does respond directly). The kinase is also stimulated by phorbol esters (18, 19) , which mimic the action of lipids and potentiate the action of calcium. Lithium has been used primarily as a tool with which to reveal the receptor-mediated stimulation of inositol phospholipid breakdown; it blocks the recycling of inositol phosphate(s) (20, 21) . Although lithium has been found to mimic and potentiate certain cholinergic effects in vivo (22) , it has not been thought to have agonist-like effects of its own.
The pituitary tumor cell line AtT-20/D16-16 synthesizes, stores, and secretes corticotropin (ACTH) (23) (24) (25) (26) . Because of its homogeneity with respect to cell type, this cell line has proved to be useful in the investigation of mechanisms regulating the processing, storage, and receptor-stimulated secretion of ACTH. ACTH secretion by these cells is responsive to a number of stimulatory and inhibitory neurotransmitters, hormones, and toxins (27) . These include corticotropin-releasing factor (CRF) (28) , isoproterenol (29) , potassium (30) , somatostatin (30, 31) , dexamethasone (28, 29, 32) , forskolin (31, 33) , and phorbol esters (32, 34) . The effects of several of these agents appear to be mediated by changes in cellular cyclic AMP (27, 33, 35) , but certain effects (of potassium, for example) are not well accounted for by changes in cyclic AMP and seem to involve calcium (35) .
We initiated an investigation of the relationship between stimulation and inhibition of ACTH secretion and inositide metabolism, using lithium as a tool. We found, however MA) in DME medium with 10% heat-inactivated fetal calf serum, streptomycin (50 pg/ml), and penicillin (50 units/ml). Cell cultures were incubated at 370C in a humidified atmosphere of 90% air/10% CO2 for 3-4 days.
AtT-20 cells. Mouse AtT-20/D16-16 tumor cells (passage 15-30) were grown and subcultured in DME medium (containing 7.2 mg of inositol per liter and 4500 mg of glucose per liter) with 10% fetal calf serum as described (28) . Cells were plated in 35-mm diameter culture cluster dishes at an initial density of 1.5 x 105 cells per well and were used 4 days after subculturing (60-80% confluency).
Experimental Procedure. Primary cultures. Three to 4 days after cell plating, the medium in each well was removed, the cells were washed twice with DME medium, and 1 ml of fresh DME medium (1000 mg of glucose per liter) containing 3 gg of bacitracin per ml and 25 mM Hepes (pH 7.4), with or without CRF (0.1 ,uM) or LiCl (10 mM), was added to the cells for various times. During the incubation period, the cells were placed in a humidified atmosphere containing 10% CO2 at 37°C. After this stimulation period, a sample of the medium (0.5 ml) was removed and centrifuged at 2000 x g to pellet any cellular material. An aliquot (0.35 ml) was removed from the uppermost portion of the supernatant and frozen at -70°C until assay for ACTH.
AtT-20 cells. Typical experiments simultaneously assessed the effects of drugs on ACTH secretion and [3H]inositide metabolism. Four days after subculturing, the medium was removed and replaced with 0.75 ml of fresh DME medium (containing 4500 mg of glucose per liter, 10% fetal calf serum, and 5 ,uCi of [ H]inositol). Cells were exposed to [3H]inositol (final concentration, 40.4 ,uM; final specific activity, 165 mCi/mmol) for 24 hr. The cells were then washed twice with DME medium and preincubated without isotope in DME medium containing 25 mM Hepes with or without drugs for 1-3 hr. After this preincubation period, the cells were washed again and incubated with the same or different agents present, usually for 40 min. Medium was removed for assay of ACTH, and the cells were killed and extracted for
[3H]inositide assay by addition of 0.8 ml of chloroform/ methanol/glacial acetic acid, 1:1:2 (vol/vol). In some experiments the cells were not exposed to [3H]inositol prior to stimulation.
[3H]Inositol itself had no effect on ACTH release. All experiments used three wells per group; each well was assayed separately. Data from such triplicates were generally within 10% of the mean.
Cyclic AMP Studies. For the cyclic AMP studies, cells
were preincubated for 15 min with DME medium containing 25 mM Hepes and 0.5 mM iBuMeXan. The cells were washed and exposed to similar medium with or without test agents for 20 min. After this time the medium was removed, and 0.5 M HCO was added to the cells. The cells were sonicated in the wells, and an aliquot (0.5 ml) of sample was lyophilized, resuspended in assay buffer, and frozen for later analysis. Cyclic AMP was determined by using the commercially available RIA kit (Becton Dickinson) as described (31 (36) as standards (unpublished observations). The procedure is a composite of modifications of published methods (37) (38) (39) . The cell extract was transferred and brought to a composition of chloroform/methanol/glacial acetic acid/water, 9:1:2:0.2 (vol/vol), by addition of 1.6 ml of chloroform. An aliquot was counted for total cellular
[3H]inositol-derived radioactivity. Lipid and nonlipid inositides were separated by passing the total (single phase) mixture through a 1-ml Sephadex G-25 column (37) [topped with sand, which had been prepared with methanol/water, 1:1 (vol/vol), followed by chloroform/methanol/glacial acetic acid/water, 19:1:2:0.3 (vol/vol)]. Remaining lipid was washed through the column with the latter solvent. Aliquots of the organic wash were dried and counted for total [3H]inositide lipid. Other aliquots were dried and analyzed by TLC (36, 38) in chloroform/methanol/10 mM diaminocyclohexanetetraacetic acid in 4.4 M NH40H, 90:65:20 (vol/vol).
[3H]Inositol and inositol phosphates were eluted from the Sephadex columns with methanol/water, 1:1 (vol/vol). Nonlipid [3H]inositides were separated by anion-exchange chromatography using 0.5 ml of Dowex AG1-X8 (formate form) (39) . Free [3H]inositol was washed through the columns with water. Glycerophosphoinositol was eluted with 5 mM sodium borate in 60 mM sodium formate, and an aliquot was assayed. Inositol monophosphates (InsP) were eluted with 100 mM formic acid in 200 mM ammonium formate, and an aliquot was assayed. Inositol bisphosphates (InsP2) and trisphosphates (InsP3) were eluted with 100 mM formic acid in 400 mM and 1000 mM ammonium formate, respectively, and aliquots were assayed for radioactivity.
ACTH Assay. ACTH immunoreactivity was measured as described (28) . The antibody used was obtained from the National Pituitary Agency and is specific for the 14-21 segment of ACTH. The assay detected as little as 3 pg of synthetic ACTH. The presence of [3H]inositol did not interfere with the assay.
RESULTS
Lithium stimulated ACTH secretion by AtT-20 cells. There was a clear effect at 1.5 mM LiCI; at 2 mM, the amount of ACTH secreted in 40 min was more than twice the control value (Fig. 1A) . Sodium chloride (10 mM), in place of LiCl, had no effect. ACTH secretion induced by LiCl was essentially linear for 40-60 min (Fig. 1B) .
Lithium also induced changes in [3Hlinositide metabolism.
The most striking and reliable effects were increases in [3H]InsP, which were visible after about 5 min and were consistently 2-3 times the control value after 20 min ( Fig. 1 A and B) . No consistent changes in any other [3H]inositide product were observed.t
In order to determine whether the effects of lithium were limited to the transformed AtT-20 cells, we compared the effects of LiCl and CRF, a physiologic stimulant of ACTH secretion, on primary cultures of rat anterior pituitary cells. Lithium also stimulated ACTH secretion in these cells (Fig.  2) . Thus, stimulation of ACTH secretion in response to lithium reflects properties of normal cells. Lithium's effectivetThin-layer chromatography of [3H]inositol-derived lipids revealed one major peak corresponding to phosphatidylinositol that accounted for about 95% of the radioactivity recovered. Zones corresponding to phosphatidylinositol phosphate and phosphatidylinositol bisphosphate contained less than 3% and 1%, respectively, of the radioactivity recovered (unpublished observations). Although there was no apparent change in the ratios of lipid products after lithium treatment, the latter peaks were too small to exclude a significant change in their amount or ratio after lithium treatment. Proc. NatL Acad ScL USA 82 (1985) secretion by several hormones (31) , also dimipished the effects of lithium on ACTH secretion and InsP.
Lithium's effectiveness as a secretagogue was reliably comparable to, but somewhat less than, that of CRF or high potassium (Table 3 , no pretreatment). Lithium's stimulation of ACTH secretion was not additive with that of CRF or potassium, although stimulation of ACTH secretion by CRF and potassium was additive. Lithium's effect on InsP correlated with its effect on ACTH secretion. However, InsP was not changed by CRF or potassium, nor did these agents alter the effect of lithium on InsP (Table 3 , no pretreatment).
Stimulation of ACTH secretion by CRF, isoproterenol, or forskolin is accompanied by large increases in cellular cyclic AMP (27) . We compared lithium's effect on cyclic AMP with that of CRF. Lithium caused a relatively small increase in cyclic AMP levels, which did not correlate with its effects on ACTH secretion (Table 3) .
Several secretagogues desensitize cells to their own effects. Such homologous desensitization is seen with CRF (40), potassium (unpublished observations), isoproterenol (41) , and phorbol esters (34) . Lithium also desensitized AtT- (Table 3) . Similar results were obtained in primary culture of anterior pituitary cells (unpublished observations). There was no (heterologous) desensitization by lithium pretreatment of the response to CRF or potassium, although these latter agents did desensitize the AtT-20 cells to their own effects under similar conditions. Neither was there desensitization by pretreatment with potassium to the effects of lithium. There was also no heterologous desensitization, in either direction, between lithium and isoproterenol (unpublished observations). Lithium's homologous desensitization was time and dose dependent; it was visible after 3 hr with 1 mM LiCl or after 1 hr with 10 mM LiCl (unpublished observations). [Basal ACTH secretion by AtT-20 cells was reduced by pretreatment with lithium in six of nine experiments (unpublished observations).]
"Desensitization" of the effects on [3H]inositide metabolism was more difficult to determine because, unlike secreted ACTH, the effects of "pretreatment" with lithium could not be washed away. Radioactivity in cellular InsP was relatively high after 3 hr of pretreatment with lithium. Subsequent exposure to lithium caused little further change in InsP and little stimulation of ACTH secretion (Table 3) . InsP was again virtually unaffected by CRF or potassium, while ACTH secretion was increased several fold. There was little effect of lithium pretreatment on cyclic AMP levels or on the response of cyclic AMP to lithium (Table 3) . There was, however, one class of secretagogues whose action was strongly affected by pretreatment with lithiumphorbol esters. Both lithium and phorbol myristate acetate (PMA) stimulated ACTH secretion; their effects were not additive ( However, these results were obtained with high concentrations of LiCl (10 mM); potentiation at lower lithium concentrations has not been excluded.]
Although lithium may affect membrane potential, its stimulation of ACTH secretion can readily be distinguished from that of high potassium. Pretreatment with dexamethasone reduced the effect of CRF or lithium but not of potassium on ACTH secretion (unpublished observations). Potassium had no effect on [3H]inositide metabolism in the presence or absence of lithium. There was no "heterologous" desensitization, in either direction, between potassium and lithium.
Lithium does not seem to be acting through cyclic AMP. It had a minimal effect on cyclic AMP levels, which did not correlate with lithium's effects on ACTH secretion. There was no interaction between lithium and isoproterenol or forskolin.
Stimulation of ACTH secretion by lithium correlated with induced changes in InsP (and InsP2). They displayed similar time and concentration dependence, both were inhibited by somatostatin or the absence of calcium, and both were "desensitized" by pretreatment with lithium. Whether lithium's effects on ACTH secretion are directly related to its effects on InsP remains to be determined. Clearly, though, increased levels of InsP are in themselves neither necessary nor sufficient for ACTH secretion. InsP was unaffected by several secretagogues and was higher after pretreatment with lithium (when secretion was minimal), than it was after initial exposure to lithium (when ACTH secretion was stimulated).
The mechanism by which lithium stimulates ACTH secretion is unknown. Lithium's action as a secretagogue does not follow from its role in current models; an additional postulate or revision is required. There are numerous candidates. If the change in InsP is relevant, then it is possible that lithium stimulates the synthesis of InsP (and InsP2) from inositol or that, like other agents, it stimulates inositol lipid breakdown, releasing diacylglycerol and inositol phosphates. There is evidence favoring a second messenger role for diacylglycerol and/or InsP3 (12, 18) . Diacylglycerol was not measured, and InsP3 was not detected in these experiments. InsP3 may still be the initial, effective agent in this system (technical factors and experimental design may have prevented its detection), but that remains to be demonstrated. It also remains possible that InsP (or InsP2) mediates the stimulation of ACTH secretion by lithium. The unique interaction between lithium and phorbol esters suggests the involvement of protein kinase C (42) . Any of the intermediates discussed above might act on protein kinase C. Alternatively, lithium might mimic calcium or potentiate activation of protein kinase C.
Regardless of its specific biochemical mechanism, lithium's action as a secretagogue suggests (as does that of phorbol esters) the involvement of inositide metabolism and protein kinase C in the regulation and stimulation of ACTH secretion and possibly of other peptide hormones or neurotransmitters. There is evidence that lithium potentiates the effects of muscarinic cholinergic stimulation in the brain (22) . It is even possible that lithium potentiates (and phorbol esters mimic) the effect of an unidentified endogenous factor on ACTH secretion. If such factors exist in vivo, then longterm pretreatment with lithium might desensitize cells to their effects.
The ability of lithium to act as an agonist (in this case a secretagogue) and to desensitize cells to other agonists (in this case phorbol esters) adds to the uses of lithium as a tool with which to study the role of inositide metabolism in cellular function. It also suggests new avenues of research into the basis of lithium's psychopharmacological effects.
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